SCHEDULE: 1Globe Capital Discloses 10.3% Stake in Crescent Biopharma

1Globe Capital LLC and Chairman Jiaqiang Li have reported a 10.3% beneficial ownership stake in Crescent Biopharma, Inc. ordinary shares.

Summary

• 1Globe Capital LLC and Jiaqiang Li collectively hold 1,425,432 ordinary shares of Crescent Biopharma, Inc.
• This ownership represents 10.3% of the company's outstanding ordinary shares.
• The percentage of class is based on 13,892,562 shares outstanding as of July 25, 2025.
• Jiaqiang Li, as Chairman of 1Globe Capital LLC, exercises shared voting and dispositive power over these shares.
• The filing is an Amendment No. 1 to a Schedule 13G, indicating a passive investment intent.

Sentiment

Score: 6

Explanation: The filing is a neutral factual report of beneficial ownership. The presence of a significant institutional investor could be seen as a positive signal, hence slightly above neutral.

Positives

• A significant institutional investor, 1Globe Capital LLC, and its Chairman, Jiaqiang Li, have taken a substantial 10.3% stake in Crescent Biopharma, Inc., potentially signaling confidence in the company's long-term prospects.

Negatives

• No specific negative information is disclosed in this ownership filing.

Risks

• No specific risks are detailed in this Schedule 13G filing, which primarily reports beneficial ownership.

Future Outlook

NA

Management Comments

• Jiaqiang Li serves as the Chairman of 1Globe Capital LLC and directly or indirectly exercises voting and dispositive power over the Issuer's shares held by 1Globe Capital LLC and as such, Mr. Li may be deemed the ultimate beneficial owner of such shares.
• Each Reporting Person disclaims beneficial ownership of such securities that are not directly owned by such Reporting Person, except to the extent of its or his pecuniary interest therein.

Industry Context

This filing indicates a significant investment in a biopharma company, which could be seen as a vote of confidence in the sector or the specific company's pipeline, especially given the long-term nature often associated with such substantial stakes.

Stakeholder Impact

• Shareholders: The disclosure of a new significant shareholder (10.3%) could be viewed positively, potentially increasing investor confidence and liquidity.

Key Dates

Keywords

Crescent Biopharma, 1Globe Capital, Jiaqiang Li, Beneficial Ownership, Schedule 13G, Biopharma, Investment, Shareholder